Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Evgeny Klyuchnikov, Ulrike Bacher, Kwang Woo Ahn, Jeanette Carreras, N. M. Kroeger, Parameswaran N. Hari, G. H. Ku, Ernesto Ayala, A. Chen, Yi-Bin Chen, J. B. Cohen, Cesar O. Freytes, Robert P. Gale, Rummurti T. Kamble, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Rodrigo Martino, A. Mussetti, Bipin N. Savani, H. C. SchoutenS. Z. Usmani, Peter H. Wiernik, Baldeep M. Wirk, Susan M. Smith, Anna Sureda, Mehdi Hamadani*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Web of Science)

Abstract

Grade 3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the long-term outcomes after allogeneic (allo-) vs autologous hematopoietic cell transplantation (auto-HCT) in the rituximab era. A total of 197 patients undergoing first reduced-intensity conditioning (RIC) allo-HCT or first auto-HCT during 2000-2012 were included. Rituximab-naive patients were excluded. Allo-HCT recipients were younger, more heavily pretreated and had a longer interval between diagnosis and HCT. The 5-year probabilities of non-relapse mortality (NRM), relapse/progression, PFS and overall survival (OS) for auto-HCT vs allo-HCT groups were 4% vs 27% (P
Original languageEnglish
Pages (from-to)58-66
JournalBone Marrow Transplantation
Volume51
Issue number1
DOIs
Publication statusPublished - Jan 2016

Cite this